Results 191 to 200 of about 2,626 (203)

The Safety and Efficacy of Anti–IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis

Journal of Allergy and Clinical Immunology: in Practice, 2019
Yuanyuan Li, Ruoxi He, Pinhua Pan
exaly  

Ciclosporin/tralokinumab

Reactions Weekly
openaire   +2 more sources

Tralokinumab/upadacitinib

Reactions Weekly
openaire   +1 more source

Tralokinumab unsuccessful for management of severe, uncontrolled asthma

The Lancet Respiratory Medicine, 2018
openaire   +2 more sources

Tralokinumab-Langzeittherapie bei mäßiger bis schwerer atopischer Dermatitis

Aktuelle Dermatologie, 2023
openaire   +1 more source

Methotrexate/Tralokinumab

Reactions Weekly
openaire   +1 more source

Tralokinumab - Anti-IL13

Dermato Mag
openaire   +1 more source

Treatment of AD with Tralokinumab

Kareem G. Elhage, Riley K. Spencer, Joy Q. Jin, Mitchell S. Davis, Marwa Hakimi, Tina Bhutani, Wilson Liao   +6 more
openaire   +1 more source

Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2

Journal of Molecular Biology, 2017
exaly  

A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers

Drug Metabolism and Pharmacokinetics, 2018
exaly